Autologous bone marrow CD133+ stem cell therapy (University of Rostock)

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameAutologous bone marrow CD133+ stem cell therapy (University of Rostock)

Drug Alias NameCD133+ autologous bone marrow stem cell therapy (IRMED)

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived

Mechanisms of ActionAngiogenesis stimulants

TargetsNot applicable

Therapy Area/IndicationsHeart Failure

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPending (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Rostock

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGerman Heart Institute Berlin-Services Gmbh

Active IndicationsN/A

Inactive IndicationsHeart Failure

Other Information

ATC CodeN/A